← Patent-cliff monitor small molecule BRAFTOVI ENCORAFENIB
Loss of exclusivity November 2032 latest FDA-listed patent expiry
Drug detail Brand name BRAFTOVI Active ingredient ENCORAFENIB Strength 50MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval June 2018 Marketing status DISCN
Listed patents Patent Expires Type 9763941 November 2032 use U-2335 9387208 November 2032 product 9314464 July 2031 use U-2336 10005761 August 2030 use U-2335 9850229 August 2030 use U-2337 9850230 August 2030 use U-2334 9593099 August 2030 substance 9593100 August 2030 product 8541575 February 2030 substance, product 8946250 July 2029 substance, product
Regulatory exclusivity Code Expires ODE-445 October 2030 I-957 December 2027 I-928 October 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.